{
    "clinical_study": {
        "@rank": "119233", 
        "arm_group": [
            {
                "arm_group_label": "Metronidazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral administration of metronidazole, 500 mg twice daily for 7 consecutive days"
            }, 
            {
                "arm_group_label": "GoldenCare", 
                "arm_group_type": "Experimental", 
                "description": "GoldenCare administered intravaginally for at least 6 hours at night for 7 consecutive nights."
            }
        ], 
        "brief_summary": {
            "textblock": "GoldenCare is a copper intravaginal device that may be useful for the treatment of\n      symptomatic bacterial Vaginosis (BV). Standard treatment for BV is metronidazole.  Although\n      the reported cure rate is as high as 90%, the recurrence rate is 58% after 12 months. The\n      study hypothesis is that GoldenCare will cure BV. This is a proof of concept study to\n      collect preliminary evidence of the safety and efficacy of GoldenCare."
        }, 
        "brief_title": "GoldenCareTM for the Treatment of Bacterial Vaginosis", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Bacterial Vaginosis", 
        "condition_browse": {
            "mesh_term": "Vaginosis, Bacterial"
        }, 
        "detailed_description": {
            "textblock": "GoldenCare is a copper intravaginal device that may be useful for the treatment of\n      symptomatic bacterial Vaginosis(BV). Standard treatment for BV is metronidazole.  Although\n      the reported cure rate is as high as 90%, the recurrence rate is 58% after 12 months. The\n      study hypothesis is that GoldenCare will cure BV. This is a proof of concept study to\n      collect preliminary evidence of the safety and efficacy of GoldenCare."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Female aged 18 years or older\n\n          -  Subject has clinical bacterial Vaginosis with 4 of 4 positive Amsel's criteria\n\n          -  Negative pregnancy test\n\n          -  For 7 day treatment period, subject agrees to refrain from using douches and\n             intravaginal products (i.e. feminine deodorant sprays, spermicides, Nonoxynol-9\n             products, tampons, and condoms). Subject also agrees to refrain from taking oral or\n             intravaginal antibiotics (unless enrolled in comparator arm),or antifungal agents\n             during the entire study period.\n\n        Exclusion Criteria:\n\n          -  Subject has another infectious or noninfectious cause of vulvovaginitis such\n             asymptomatic candidiasis, Trichomonas vaginalis, Chlamydia trachomatis, Neisseria\n             gonorrhoeae, Herpes simplex, human papilloma virus, atrophic vaginitis, lichen\n             sclerosus, or genital warts."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762670", 
            "org_study_id": "CDA 1106"
        }, 
        "intervention": [
            {
                "arm_group_label": "GoldenCare", 
                "intervention_name": "GoldenCare", 
                "intervention_type": "Drug", 
                "other_name": "Copper intravaginal device"
            }, 
            {
                "arm_group_label": "Metronidazole", 
                "description": "500 mg twice daily for 7 days", 
                "intervention_name": "Metronidazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metronidazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Bacterial Vaginosis", 
            "BV"
        ], 
        "lastchanged_date": "July 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Harper University Hospital Department of Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19140"
                    }, 
                    "name": "Temple University Hospital Department of OB/GYN"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized Study to Determine the Safety and Efficacy of GoldenCareTM for the Treatment of Bacterial Vaginosis", 
        "overall_official": {
            "affiliation": "Temple University Hospital Department of OB/GYN", 
            "last_name": "Ashwin Chatwani, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Successful clinical cure of BV is defined as all 4 Amsel's criteria negative at Visit 4 and a Nugent score of 0-3 at Visit 4.  Success will be determined at 21 to 30 days after first treatment.", 
            "measure": "Safety and efficacy of treating BV with GoldenCare for 7 days", 
            "safety_issue": "No", 
            "time_frame": "21 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762670"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CDA Research Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CDA Research Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013", 
        "why_stopped": "Company decided to stop study for reasons other than safety"
    }
}